Bertin Pharma and LXRepair sign up an agreement for manufacturing and distributing a kit to quantify DNA repair enzyme activities : Glyco-SPOT DNA Repair Assay kit
Bertin Pharma reiterates its top position in the categories "regulatory affairs" and "productivity" in the survey conducted by the company Nice Insight.
Bertin Pharma is completing its existing range of assay products dedicated to Obesity-Diabetes pathologies: 7 human and rat/mouse EIA kits available to assay the specific hormone secreted primarily by cells of the stomach: Ghrelin.
On January 31st, 2014, Bertin Pharma, a Bertin Technologies subsidiary specialising in pharmaceutical R&D contract services and a bioreagent supplier, has acquired a 1500 sqm. R&D facility located in Martillac (south-west of France) dedicated to the formulation and the production of clinical batches of over-the-counter (OTC) drugs from Johnson & Johnson Santé Beauté France (JJSBF).
In addition to the acquisition of the R&D facility, the transaction includes the entry into a services agreement through which Bertin Pharma will provide R&D services to JJSBF.
Harlan Contract Research Services and Bertin Pharma, headquartered in Montigny-le-Bretonneux, France, announced a strategic partnership to offer a comprehensive package for early drug development. Under the agreement, the companies will offer a wider range of drug discovery and translational medicine services, including expanded profiling and molecule testing, especially in the context of regulatory
It will be used for research on infectious diseases, vaccines and antivirals. Proposed at the initiative of three partners: CEA, Université Paris Sud and Bertin Pharma, the project won the tender EquipEx 2010 (Future Investments, Equipment of Excellence) and adds activities cytometry platform FlowCyTech service immunovirology CEA. The joint offering services Bertin Pharma and CEA was presented on this occasion, as the PharmImmune.